Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia
Review statusPeer Review
MetadataShow full item record
Nkando, I., Perez-Casal, J., Mwirigi, M., Prysliak, T., Townsend, H., Berberov, E., Kuria, J., Mugambi, J., Soi, R., Liljander, A., Jores, J., Gerdts, V., Potter, A., Naessens, J. and Wesonga, H. 2016. Recombinant Mycoplasma mycoides proteins elicit protective immune responses against contagious bovine pleuropneumonia. Veterinary Immunology and Immunopathology 171:103–114.
Permanent link to cite or share this item: http://hdl.handle.net/10568/72741
Mycoplasma mycoides subsp. mycoides (Mmm) is the causative agent of contagious bovine pleuropneumonia (CBPP), a devastating respiratory disease mainly affecting cattle in sub-Saharan Africa. The current vaccines are based on live-attenuated Mmmstrains and present problems with temperature stability, duration of immunity and adverse reactions, thus new vaccines are needed to overcome these issues. We used a reverse vaccinology approach to identify 66 Mmm potential vaccine candidates. The selection and grouping of the antigens was based on the presence of specific antibodies in sera from CBPP-positive animals. The antigens were used to immunize male Boran cattle (Bos indicus) followed by a challenge with the Mmm strain Afadé. Two of the groups immunized with five proteins each showed protection after the Mmm challenge (Groups A and C; P < 0.05) and in one group (Group C) Mmm could not be cultured from lung specimens. A third group (Group N) showed a reduced number of animals with lesions and the cultures for Mmm were also negative. While immunization with some of the antigens conferred protection, others may have increased immune-related pathology. This is the first report that Mmm recombinant proteins have been successfully used to formulate a prototype vaccine and these results pave the way for the development of a novel commercial vaccine.